CytoDyn Stock Price, News & Analysis (OTCMKTS:CYDY)

$0.76 0.00 (0.00 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$0.76
Today's Range$0.72 - $0.78
52-Week Range$0.46 - $0.84
Volume364,194 shs
Average Volume291,236 shs
Market Capitalization$143.70 million
P/E Ratio-3.04
Dividend YieldN/A
Beta0.82

About CytoDyn (OTCMKTS:CYDY)

CytoDyn logoCytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:CYDY
CUSIPN/A
Phone+1-360-9808524

Debt

Debt-to-Equity RatioN/A
Current Ratio0.28%
Quick Ratio0.28%

Price-To-Earnings

Trailing P/E Ratio-3.04
Forward P/E Ratio-3.30
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.01) per share
Price / Book-76.00

Profitability

Trailing EPS($0.25)
Net Income$-25,760,000.00
Net MarginsN/A
Return on Equity-10,003.02%
Return on Assets-423.72%

Miscellaneous

Employees146
Outstanding Shares189,080,000

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) released its earnings results on Tuesday, October, 10th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.03. View CytoDyn's Earnings History.

When will CytoDyn make its next earnings announcement?

CytoDyn is scheduled to release their next quarterly earnings announcement on Friday, February, 23rd 2018. View Earnings Estimates for CytoDyn.

Where is CytoDyn's stock going? Where will CytoDyn's stock price be in 2018?

1 Wall Street analysts have issued twelve-month price targets for CytoDyn's shares. Their predictions range from $2.00 to $2.00. On average, they expect CytoDyn's stock price to reach $2.00 in the next twelve months. View Analyst Ratings for CytoDyn.

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:

  • Anthony D. Caracciolo, Independent Chairman of the Board (Age 60)
  • Nader Z. Pourhassan Ph.D., President, Chief Executive Officer, Director (Age 52)
  • Michael D. Mulholland, Chief Financial Officer, Treasurer, Corporate Secretary (Age 63)
  • Denis R. Burger Ph.D., Director (Age 70)
  • Carl C Dockery, Director (Age 53)
  • Gregory A. Gould CPA, Independent Director (Age 50)
  • A. Bruce Montgomery M.D., Independent Director (Age 63)
  • Jordan G. Naydenov, Independent Director (Age 54)

How do I buy CytoDyn stock?

Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CytoDyn stock can currently be purchased for approximately $0.76.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $143.70 million. The biotechnology company earns $-25,760,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. CytoDyn employs 146 workers across the globe.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 Main St Ste 660, VANCOUVER, WA 98660-2970, United States. The biotechnology company can be reached via phone at +1-360-9808524 or via email at [email protected]


MarketBeat Community Rating for CytoDyn (CYDY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytoDyn (OTCMKTS:CYDY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.00$2.00$2.00$1.80
Price Target Upside: 220.00% upside233.33% upside179.04% upside151.13% upside

CytoDyn (OTCMKTS:CYDY) Consensus Price Target History

Price Target History for CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS:CYDY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/13/2018HC WainwrightSet Price TargetBuy$2.00View Rating Details
10/6/2016Rodman & RenshawInitiated CoverageBuy$1.60View Rating Details
(Data available from 2/19/2016 forward)

Earnings

CytoDyn (OTCMKTS:CYDY) Earnings History and Estimates Chart

Earnings by Quarter for CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS CYDY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2018        
10/10/2017Q1 2018($0.05)($0.08)ViewN/AView Earnings Details
7/20/2017Q4 2017($0.05)ViewN/AView Earnings Details
4/13/2017Q3 2017($0.04)($0.06)ViewN/AView Earnings Details
1/13/2017Q2 2017($0.04)($0.05)ViewN/AView Earnings Details
10/12/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
7/19/2016Q4 2016($0.05)ViewN/AView Earnings Details
4/13/2016Q3 2016($0.05)ViewN/AView Earnings Details
1/11/2016Q2 2016($0.06)ViewN/AView Earnings Details
10/9/2015Q1 2016($0.12)ViewN/AView Earnings Details
7/10/2015Q4 2015($0.24)ViewN/AView Earnings Details
4/10/2015Q3 2015($0.05)ViewN/AView Earnings Details
1/12/2015Q2 2015($0.09)ViewN/AView Earnings Details
10/10/2014Q1 2015($0.06)ViewN/AView Earnings Details
7/18/2014Q4 2014($0.05)ViewN/AView Earnings Details
4/11/2014Q3 2014($0.06)ViewN/AView Earnings Details
1/13/2014Q2 2014($0.08)ViewN/AView Earnings Details
10/15/2013Q1 2014($0.08)ViewN/AView Earnings Details
8/29/2013Q4 2013($0.08)ViewN/AView Earnings Details
4/12/2013Q3 2013($0.08)ViewN/AView Earnings Details
1/14/2013Q2 2013($0.06)ViewN/AView Earnings Details
10/9/2012Q1 2013($0.10)ViewN/AView Earnings Details
8/22/2012Q4 2012($0.13)ViewN/AView Earnings Details
4/16/2012Q3 2012($0.06)ViewN/AView Earnings Details
1/17/2012Q2 2012($0.07)ViewN/AView Earnings Details
11/22/2011Q1 2012($0.05)ViewN/AView Earnings Details
11/3/2011Q4 2011($0.05)ViewN/AView Earnings Details
10/7/2011Q3 2011($0.05)ViewN/AView Earnings Details
1/14/2011Q2 2011($0.05)ViewN/AView Earnings Details
12/14/2010Q1 2011($0.03)ViewN/AView Earnings Details
12/3/2010Q4 2010($0.42)ViewN/AView Earnings Details
10/25/2010Q3 2010($0.04)ViewN/AView Earnings Details
9/28/2010Q2 2010($0.04)ViewN/AView Earnings Details
8/31/2010Q1 2010($0.02)ViewN/AView Earnings Details
6/23/2010Q3 2009($0.02)ViewN/AView Earnings Details
6/3/2010Q2 2009($0.05)ViewN/AView Earnings Details
5/20/2010Q1 2009($0.04)ViewN/AView Earnings Details
3/12/2010Q4 2008($0.04)ViewN/AView Earnings Details
12/1/2009Q3 2008($0.02)ViewN/AView Earnings Details
9/25/2009Q1 2008($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CytoDyn (OTCMKTS:CYDY) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.23 EPS
Next Year EPS Consensus Estimate: $-0.16 EPS

Dividends

Dividend History for CytoDyn (OTCMKTS:CYDY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CytoDyn (OTCMKTS CYDY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 0.13%
Insider Trades by Quarter for CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS CYDY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/21/2016Nader PourhassanInsiderBuy15,000$0.66$9,900.0060,056View SEC Filing  
10/17/2016Michael D MulhollandCFOBuy11,000$0.66$7,260.0037,043View SEC Filing  
10/30/2014Anthony CaraccioloDirectorBuy26,000$0.72$18,720.00View SEC Filing  
10/15/2014Michael D MulhollandCFOBuy2,500$0.79$1,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytoDyn (OTCMKTS CYDY) News Headlines

Source:
DateHeadline
CytoDyn (CYDY) Given a $2.00 Price Target at HC WainwrightCytoDyn (CYDY) Given a $2.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 18 at 7:00 PM
CytoDyn (CYDY) Cut to Sell at Zacks Investment ResearchCytoDyn (CYDY) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - February 12 at 10:12 PM
CytoDyn (CYDY) Raised to "Hold" at Zacks Investment ResearchCytoDyn (CYDY) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 6 at 9:28 PM
CytoDyn (CYDY) Lowered to Sell at Zacks Investment ResearchCytoDyn (CYDY) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 31 at 10:24 PM
CytoDyn (CYDY) Receives Buy Rating from HC WainwrightCytoDyn (CYDY) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - December 8 at 7:38 PM
HC Wainwright Reaffirms Buy Rating for CytoDyn (CYDY)HC Wainwright Reaffirms Buy Rating for CytoDyn (CYDY)
www.americanbankingnews.com - November 29 at 12:22 PM
Cytodyn Is Worth A Look Before Phase 3 HIV Data - Seeking AlphaCytodyn Is Worth A Look Before Phase 3 HIV Data - Seeking Alpha
seekingalpha.com - November 21 at 4:45 AM
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell TransplantationCytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation
finance.yahoo.com - November 14 at 6:10 PM
CytoDyns Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - GlobeNewswire (press release)CytoDyn's Two-Year Update on Its PRO 140 Monotherapy Study in HIV Accepted at CROI 2017 - GlobeNewswire (press release)
globenewswire.com - November 17 at 8:48 AM
CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 ... - GlobeNewswire (press release)CytoDyn Files Protocol for Extended Access to PRO 140 for Patients Who Reach the End of PRO 140 Pivotal Phase 3 ... - GlobeNewswire (press release)
globenewswire.com - October 24 at 9:45 AM
SeeThruEquity Issues Update on CytoDyn Inc. (CYDY) and Raises Target to $3.75 - Baystreet.caSeeThruEquity Issues Update on CytoDyn Inc. (CYDY) and Raises Target to $3.75 - Baystreet.ca
www.baystreet.ca - October 21 at 4:34 PM
CYTODYN INC. Files SEC form 10-Q, Quarterly ReportCYTODYN INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - October 12 at 4:47 PM
Coherus Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz - NasdaqCoherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz - Nasdaq
www.nasdaq.com - October 7 at 4:28 PM
CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After ... - GlobeNewswire (press release)CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After ... - GlobeNewswire (press release)
globenewswire.com - October 6 at 10:04 AM
CytoDyn inks $9M direct equity offering; shares off 16% - Seeking AlphaCytoDyn inks $9M direct equity offering; shares off 16% - Seeking Alpha
seekingalpha.com - September 12 at 4:21 PM
CytoDyn Announces $10.0 Million Registered Direct Offering - GlobeNewswire (press release)CytoDyn Announces $10.0 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - September 12 at 4:21 PM
CYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and ECYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E
biz.yahoo.com - September 12 at 9:25 AM
CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 - GlobeNewswire (press release)CytoDyn to Present at Rodman & Renshaw Global Investment Conference on September 12 - GlobeNewswire (press release)
globenewswire.com - September 8 at 8:20 AM

SEC Filings

CytoDyn (OTCMKTS:CYDY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

CytoDyn (OTCMKTS CYDY) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.